Biotech Values

[iwfal]

ONTY -

Also Kirkman gave out enough info on trial design (90% powered 6 mo MST advantage over control arm MST of 20 mos, HR .76-.77, and overall p value .025) to know that Merck designed START with .025 one sided under assumption of PH.

Hopefully that puts to bed the weird assumption that 0.025 was single sided. (BTW - I confirmed your calcs that HR=20/26, 90 percent powering, and 0.05 traditional two-sided alpha align with 700 events.)